161696-76-0

Basic information

• Product Name: 2-Methyl-4-(1-piperazinyl)-10H-thienol[2,3-b][1,5]benzodiazepine
• Synonyms: 2-Methyl-4-(1-Piperazinyl)-10H-Thieno-[2,3-b][1,5]Benzodiazepine;4'-Desmethylolanzapine;Desmethylolanzapine;LY 170055;2-METHYL-4-(1-PIPERAZINYL)-10H-THIENOL[2,3-B][1,5]BENZODIAZEPINE;10H-Thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(1-piperazinyl)-;Desmethylolanzapine dihydrochloride;Olanzapine N-DesMethyl Metabolite
• CAS NO: 161696-76-0
• Molecular Formula: C₁₆H₁₈N₄S
• Molecular Weight: 298.40592
• Product Categories: Metabolites;Olanzapine
• Mol File: 161696-76-0.mol
• Article Data: 9

Chemical Properties

• Melting Point: 144.5°C
• Boiling Point: 489.2°C at 760 mmHg
• Flash Point: 13℃
• Appearance: /
• Density: 1.38g/cm³
• Vapor Pressure: 1.02E-09mmHg at 25°C
• Refractive Index: 1.742
• Storage Temp.: -20°C Freezer
• PKA: 8.58±0.10(Predicted)
• CAS DataBase Reference: 2-Methyl-4-(1-piperazinyl)-10H-thienol[2,3-b][1,5]benzodiazepine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-4-(1-piperazinyl)-10H-thienol[2,3-b][1,5]benzodiazepine(161696-76-0)
• EPA Substance Registry System: 2-Methyl-4-(1-piperazinyl)-10H-thienol[2,3-b][1,5]benzodiazepine(161696-76-0)

Safety Data

• Hazard Codes: F,Xn
• Statements: 11-20/21/22-36
• Safety Statements: 16-26-36/37
• RIDADR: UN 1648 3 / PGII
• WGK Germany: 2
• Hazardous Substances Data: 161696-76-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-4-(1-piperazinyl)-10H-thienol[2,3-b][1,5]benzodiazepine is used as a metabolite in the pharmaceutical industry for the development and analysis of atypical antipsychotic medications, specifically olanzapine. Its role in the industry is crucial for understanding the metabolic pathways and effects of olanzapine, which can help in the development of more effective and safer antipsychotic drugs.
Used in Clinical Toxicology:
In the field of clinical toxicology, 2-Methyl-4-(1-piperazinyl)-10H-thienol[2,3-b][1,5]benzodiazepine is utilized as a reference compound for the analysis of olanzapine levels in biological samples. This helps in determining the safety and efficacy of the drug in patients, as well as monitoring potential drug interactions and side effects.
Used in Forensic Testing:
2-Methyl-4-(1-piperazinyl)-10H-thienol[2,3-b][1,5]benzodiazepine is employed as a forensic testing standard for the detection and quantification of olanzapine in various samples, such as blood, urine, or tissue. This is essential for cases involving drug-related fatalities, drug-facilitated crimes, or the assessment of drug use in individuals.
Used in Therapeutic Drug Monitoring:
In the context of therapeutic drug monitoring, 2-Methyl-4-(1-piperazinyl)-10H-thienol[2,3-b][1,5]benzodiazepine serves as a valuable tool for assessing the optimal dosage and treatment regimen for patients undergoing olanzapine therapy. By monitoring the levels of this metabolite, healthcare professionals can ensure that patients receive the most effective and safe treatment for their conditions.

InChI:InChI=1/C16H18N4S/c1-11-10-12-15(20-8-6-17-7-9-20)18-13-4-2-3-5-14(13)19-16(12)21-11/h2-5,10,17,19H,6-9H2,1H3

Upstream product

• 132539-06-1 zyprexa 
• 138564-60-0 4-amino-2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine hydrochloride 
• 930836-40-1 tert-butyl 4-(2-methyl-10H-benzo[b]thieno[2,3-e][1,4]diazepin-4-yl)piperazine-1-carboxylate 
• 1428146-26-2 ethyl 4-(2-methyl-10H-benzo[b]thieno[2,3-e][1,4]diazepin-4-yl)piperazine-1-carboxylate 
• 138564-59-7 2-(2-nitroanilino)-5-methylthiophene-3-carbonitrile 
• 1493-27-2 ortho-nitrofluorobenzene 
• 110-85-0 piperazine 
• 612503-08-9 2-methyl-10H-benzo[b]thieno[2,3-e][1,4]diazepin-4-amine 
• 138564-58-6 2-amino-5-methylthiophene-3-carbonitrile 

Downstream Products

• 132539-06-1 zyprexa 

Relevant articles and documents

Butyl methacrylate-co-ethylene glycol dimethacrylate monolith for online in-tube SPME-UHPLC-MS/MS to determine chlopromazine, clozapine, quetiapine, olanzapine, and their metabolites in plasma samples

This manuscript describes a sensitive, selective, and online in-tube solid-phase microextraction coupled with an ultrahigh performance liquid chromatography-tandem mass spectrometry (in-tube SPME-UHPLC-MS/MS) method to determine chlopromazine, clozapine, quetiapine, olanzapine, and their metabolites in plasma samples from schizophrenic patients. Organic poly(butyl methacrylate-co-ethylene glycol dimethacrylate) monolith was synthesized on the internal surface of a fused silica capillary (covalent bonds) for in-tube SPME. Analyte extraction and analysis was conducted by connecting the monolithic capillary to an UHPLC-MS/MS system. The monolith was characterized by scanning electron microscopy (SEM) and Fourier transform infrared spectrometry (FTIR). The developed method presented adequate linearity for all the target antipsychotics: R2 was higher than 0.9975, lack-of-fit ranged from 0.115 to 0.955, precision had variation coefficients lower than 14.2%, and accuracy had relative standard error values ranging from ?13.5% to 14.6%, with the exception of the lower limit of quantification (LLOQ). The LLOQ values in plasma samples were 10 ng mL?1 for all analytes. The developed method was successfully applied to determine antipsychotics and their metabolites in plasma samples from schizophrenic patients.

Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3

Objective The antipsychotic olanzapine is reportedly metabolized by inducible human cytochrome P450 (CYP) 1A2 and variable copy-number CYP2D6 and polymorphic flavin-containing monooxygenase 3 (FMO3) in different pathways. We investigated individual differences in the metabolite formation and clearance of olanzapine in vitro and in vivo. Methods Human liver microsomal olanzapine oxidation activities were evaluated, and plasma concentrations of olanzapine were determined in 21 Japanese patients (mean age: 50 years, range: 32-69 years, 14 male and 7 female, including 6 smokers) genotyped for CYP2D6 (1,5, and10) and FMO3 (E158K, C197fsX, R205C, V257M, E308G, and R500X). Results Furafylline (a CYP1A2 inhibitor), quinidine (a CYP2D6 inhibitor), and heat treatment (inactivates FMO3) suppressed liver microsomal metabolic clearance of olanzapine by approximately 30%. Olanzapine N-demethylation and N-oxygenation were found to be catalyzed by CYP1A2 and CYP2D6 and by CYP2D6 and FMO3, respectively, in experiments using liver microsomes and recombinant enzymes. Plasma concentrations and clearance of olanzapine were not affected by CYP2D6 or FMO3 genotypes or smoking behavior. Conclusions Olanzapine clearance was not affected by CYP2D6 or FMO3 genotypes or smoking behavior as a single factor under the present conditions because olanzapine clearance is mediated by multiple enzymes involved in two major and one minor pathways.

[11C]Olanzapine, radiosynthesis and lipophilicity of a new potential PET 5-HT2 and D2 receptor radioligand

Olanzapine and its precursor desmethyl-Olanzapine were synthesized from malononitrile, propionaldehyde, 1-fluoro-2-nitrobenzene, and substituted piperazine in 4, 4, 5, and 5 steps with 35%, 32%, 26%, and 32% overall chemical yield, respectively. [11C]Olanzapine was prepared from desmethyl-Olanzapine with [11C]CH3OTf through N-[ 11C]methylation and isolated by HPLC combined with solid-phase extraction (SPE) in 40-50% radiochemical yield based on [11C]CO 2 and decay corrected to end of bombardment (EOB), with 370-740 GBq/μmol specific activity at EOB. The calculated Log P (C Log P) value of [11C]Olanzapine is 3.39.

NOVEL PSYCHOTROPIC AGENTS HAVING GLUTAMATE NMDA ACTIVITY

The invention provides novel compounds and pharmaceutical compositions for the treatment of psychological and/or psychiatric diseases or disorders.

METHOD FOR PREPARING A MIXED SOLVATE OF 0LANZAPINE

An improved method is provided for preparing a mixed solvate of olanzapine/water/tetrahydrofuran in a proportion of 1:1:1/2. Said improvement is characterised in that said mixed solvate is basically prepared by means of methylation of the N-desmethylolanzapine with dimethyl sulphate, using tetrahydrofuran and water as solvents.

A PROCESS FOR THE PREPARATION OF N-DEMETHYLOLANZAPINE

The invention relates to the process for the preparation of N- demethylolanzapine and the use of N-demethylolanzapine obtained by the process for the preparation of antipsychotic medicament olanzapine. According to the process of the invention the reaction of an- hydrous piperazine with 4-amino-2-methyl-10H-thieno[2.3-b]- [1.5]benzodiazepine or its inorganic acid addition salt is carried out in molten piperazine, in the absence of a solvent.

Process for preparing olanzapine

A process for preparing olanzapine comprising methylation of N-demethyl olanzapine with a methylating agent in a solvent comprising dichloromethane, methanol, or a mixture thereof.

SYNTHESIS OF 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2, 3-B][1,5]BENZODIAZEPINE AND SALTS THEREOF

The invention belongs to the field of organic chemistry and relates to a new process for the purification of olanzapine comprising preparation of acid addition salts of olanzapine and transformation thereof into a pharmaceutically acceptable pure and discoloured final product. The present invention also relates to new processes for the preparation of pure olanzapine.

The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053)

4'-N-desmethyl olanzapine (2), olanzapine 4'-N-oxide (3) and 2-hydroxymethyl olanzapine (5), have been prepared and their pharmacology compared to that of the parent compound olanzapine (1). The 4'-N-quaternary glucuronide (8) has also been prepared.